Moderna (NASDAQ:MRNA) PT Raised to $150.00 at Cowen

Moderna (NASDAQ:MRNA – Get Rating) had its price target hoisted by equities research analysts at Cowen from $130.00 to $150.00 in a report released on Wednesday, The Fly reports. Cowen’s target price suggests a potential downside of 23.76% from the company’s current price.

Other analysts also recently issued research reports about the stock. Morgan Stanley decreased their price target on shares of Moderna from $209.00 to $205.00 and set an “equal weight” rating for the company in a research note on Tuesday. Jefferies Financial Group raised shares of Moderna from a “hold” rating to a “buy” rating and boosted their price objective for the company from $170.00 to $275.00 in a report on Monday, December 19th. SVB Leerink boosted their price objective on shares of Moderna from $102.00 to $111.00 and gave the company a “market perform” rating in a report on Wednesday, January 18th. Cowen decreased their price objective on shares of Moderna from $165.00 to $145.00 in a research report on Thursday, October 20th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Moderna from $185.00 to $225.00 in a research note on Wednesday, January 11th. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $192.00.

Moderna Trading Down 0.1 %

Shares of MRNA stock opened at $196.76 on Wednesday. Moderna has a 52-week low of $115.03 and a 52-week high of $217.25. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.80 and a current ratio of 2.10. The firm has a market capitalization of $75.59 billion, a PE ratio of 7.12 and a beta of 1.71. The stock has a fifty day simple moving average of $185.97 and a two-hundred day simple moving average of $161.27.

Moderna (NASDAQ:MRNA – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $2.53 earnings per share for the quarter, missing analysts’ consensus estimates of $3.04 by ($0.51). Moderna had a net margin of 55.00% and a return on equity of 70.03%. The firm had revenue of $3.36 billion for the quarter, compared to analysts’ expectations of $3.33 billion. On average, analysts predict that Moderna will post 21.31 EPS for the current fiscal year.

Insiders Place Their Bets

In other Moderna news, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $200.20, for a total transaction of $2,002,000.00. Following the sale, the director now directly owns 2,247,209 shares in the company, valued at approximately $449,891,241.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $192.06, for a total value of $7,682,400.00. Following the transaction, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at approximately $1,039,418,348.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $200.20, for a total transaction of $2,002,000.00. Following the completion of the transaction, the director now directly owns 2,247,209 shares in the company, valued at $449,891,241.80. The disclosure for this sale can be found here. Insiders have sold a total of 445,899 shares of company stock worth $80,212,386 in the last ninety days. 17.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MRNA. Total Clarity Wealth Management Inc. purchased a new position in shares of Moderna in the 2nd quarter valued at $25,000. Ronald Blue Trust Inc. grew its position in Moderna by 307.4% during the 4th quarter. Ronald Blue Trust Inc. now owns 220 shares of the company’s stock worth $26,000 after purchasing an additional 166 shares during the last quarter. Evoke Wealth LLC grew its position in Moderna by 100.8% during the 3rd quarter. Evoke Wealth LLC now owns 239 shares of the company’s stock worth $28,000 after purchasing an additional 120 shares during the last quarter. Guardian Wealth Advisors LLC purchased a new position in Moderna during the 3rd quarter worth $28,000. Finally, FinTrust Capital Advisors LLC grew its position in Moderna by 754.5% during the 2nd quarter. FinTrust Capital Advisors LLC now owns 188 shares of the company’s stock worth $31,000 after purchasing an additional 166 shares during the last quarter. 63.11% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.